MONTREAL, June 12 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has been awarded a development contract from Pear Tree Pharmaceuticals, Inc. at its PharmaForm subsidiary located in Austin, Texas, for the development of two different drug products for treatment of atrophic vaginitis. PharmaForm will develop the drug products to deliver Pear Tree’s confidential drug substances to the vaginal cavity.
